Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoldonrasib - REVOLUTION Medicines

Next Previous
Drug Profile

Zoldonrasib - REVOLUTION Medicines

Alternative Names: RMC-9805

Latest Information Update: 27 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVOLUTION Medicines
  • Class Acetamides; Antineoplastics; Azabicyclo compounds; Aziridines; Cyclopentanes; Esters; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Indoles; Ketones; Methyl ethers; Morpholines; Piperazines; Pyridazines; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Preclinical Colorectal cancer

Most Recent Events

  • 19 Apr 2026 Efficacy and adverse events data from a phase I/Ib trial in Solid tumours released by Revolution Medicines
  • 26 Feb 2026 Phase-III clinical trials in Adenocarcinoma (First-line therapy, Combination therapy, Metastatic disease) (PO)
  • 26 Feb 2026 Revolution Medicines plans the phase III RASolute 308 trial for Non-small cell lung cancer (First-line therapy, Combination therapy, Metastatic disease) in second half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top